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Summary
PRINCIPLES: The literature has described opinion leaders
not only as marketing tools of the pharmaceutical industry,
but also as educators promoting good clinical practice. This
qualitative study addresses the distinction between the
opinion-leader-as-marketing-tool and the opinion-leader-
as-educator, as it is revealed in the discourses of physicians
and experts, focusing on the prescription of antidepress-
ants. We explore the relational dynamic between physi-
cians, opinion leaders and the pharmaceutical industry in
an area of French-speaking Switzerland.
METHODS: Qualitative content analysis of 24 semistruc-
tured interviews with physicians and local experts in psy-
chopharmacology, complemented by direct observation of
educational events led by the experts, which were all
sponsored by various pharmaceutical companies.
RESULTS: Both physicians and experts were critical of
the pharmaceutical industry and its use of opinion leaders.
Local experts, in contrast, were perceived by the physicians
as critical of the industry and, therefore, as a legitimate
source of information. Local experts did not consider them-
selves opinion leaders and argued that they remained intel-
lectually independent from the industry. Field observations
confirmed that local experts criticised the industry at con-
tinuing medical education events.
CONCLUSIONS: Local experts were vocal critics of the
industry, which nevertheless sponsor their continuing edu-
cation. This critical attitude enhanced their credibility in
the eyes of the prescribing physicians. We discuss how the
experts, despite their critical attitude, might still be benefi-
cial to the industry’s interests.
Key words: prescription; opinion leaders; pharmaceutical
industry criticism; marketing strategies; antidepressants
Introduction
There is significant evidence of the influence of pharma-
ceutical companies’ marketing strategies on physicians’
opinions, behaviours and prescribing patterns [1–8]. These
strategies include: direct contact with sales representatives;
production of promotional material; distribution of station-
ery and gadgets embossed with the brand’s logo; sponsor-
ship of research projects, scientific conferences, and edu-
cational events; and collaboration with so-called “opinion
leaders” [3, 9].
Opinion leaders are defined as experts exerting influence
on physicians’ decision making: eminent physicians or re-
searchers, respected by the medical community, speakers
at scientific conferences, members of advisory boards for
the pharmaceutical industry and regulation agencies, parti-
cipants in consensus conferences, and leaders in continuing
medical education [9–16]. The pharmaceutical industry has
identified opinion leaders as a major element of its mar-
keting strategy since the 1950s: from then on, the industry
has been actively recruiting such influential figures, using
various strategies, including direct payment [10]. From the
perspective of the pharmaceutical industry, the return on
investment of a “doctor’s talk” to physicians has been re-
ported as twice that of drug representatives [17]. The liter-
ature tends to view the influence of opinion leaders as neg-
ative, serving the industry’s interests [9–17].
Another trend in the literature casts opinion leaders as edu-
cators, promoting evidence-based clinical practice, devel-
oping guidelines and leading quality improvement projects.
Opinion leaders as educators are often described as “local”
colleagues the prescribers know personally [18–24].
In this article, we report on a study involving two steps,
which allowed us to explore these contrasting notions of
opinion leader. The first step was inductive, and explored
the relationships between physicians and the pharmaceut-
ical industry, focusing on the prescription of antidepress-
ants. In the interviews, local experts in psychopharmaco-
logy emerged as a major influence, a trusted source of
scientific, unbiased information; notably, they were per-
ceived as independent from the pharmaceutical industry.
These experts were involved in continuing education in the
area. However, these activities were all sponsored by phar-
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maceutical companies; therefore, we wondered how the ex-
perts perceived their own role as potential opinion leaders,
their influence on their colleagues, and their relationship
with the pharmaceutical industry. This led us to design a
second step, based on initial findings, to explore these is-
sues with them.
Our study explored the distinction between the opinion-
leader-as-marketing-tool and the opinion-leader-as-educat-
or, as it revealed itself in the discourses of physicians and
experts. We suggest the boundaries are perhaps less clear-
cut than they appear.
Methods
Sample and data collection
This article reports results based on data collected in two
distinct, consecutive steps. The first step was part of a lar-
ger study [25] on the factors influencing the prescription of
antidepressant drugs. At this stage, the first author recruited
a convenience sample of 20 physicians, either through pre-
vious acquaintance or by approaching them at continuing
education events (workshops in medical congresses and
teaching rounds in psychopharmacology organised by the
local university hospital). The only criterion for inclusion
was prescription of antidepressant drugs. We included 8
general practitioners and 12 psychiatrists. Most worked in
an outpatient setting, and there was a mix between private
practice and public institutions. All had 10 years or more
of professional experience. Hereinafter, we shall call them
“prescribing physicians”. The first author conducted indi-
vidual, nondirective interviews with these 20 participants,
exploring factors influencing antidepressant prescription.
She audio-recorded these interviews and then transcribed
them verbatim.
In these interviews, local experts in psychopharmacology
emerged as the major source of trusted information for
prescribing physicians. We name these experts “local” be-
cause they were mostly active in a part of French-speaking
Switzerland, where they led regular continuing medical
education events (conferences and teaching rounds in psy-
chopharmacology). These experts were also “local” in that
prescribing physicians knew them personally, at least to
some extent (e.g., they were available for clinical advice on
demand). Based on initial findings, we decided to recruit an
additional sample of four local experts. Two of them were
identified by the prescribing physicians, while the two oth-
ers were identified by the research team as they had had a
similar profile of being locally respected and well known
for their expertise in psychopharmacology. The research
group designed a semidirective interview protocol to ex-
plore the local experts’ own perception of opinion leaders
in general, their own role as opinion leader, and the nature
of their relationships with the pharmaceutical industry (see
annex). The first author conducted the audio-recorded in-
terviews and transcribed them verbatim.
Finally, we completed the interview material with direct
observation of the experts engaged in continuing education
activities (see appendix for a description of the events). The
first author was a nonparticipant observer and took field
notes summarising the content of the discussions that took
place, with a specific focus on aspects related to the first
findings of the interviews with the local experts.
Analysis
The first author analysed the 20 interviews with the pre-
scribing physicians, using qualitative content analysis to
identify core themes (i.e., themes which are important in
the description of the explored phenomenon) [26–28]. At
this point, the research group reached a consensus on two
themes felt to deserve further exploration: (i) a very critical
perception of the pharmaceutical industry as manipulative
and dishonest, and (ii) a very positive perception of local
experts. These themes informed the design of the semi-dir-
ective interview with local experts.
The first two authors analysed the interviews with the four
local experts in parallel. Two major issues emerged from
close and iterative reading of the transcripts: (i) a critical
attitude toward the pharmaceutical industry and opinion
leaders in general, and (ii) a sense of preserving one’s inde-
pendence from the pharmaceutical industry.
In the results section, we present the analysed data and il-
lustrative quotes from all the interviews (n = 24), under
two general headings: “Criticism of the pharmaceutical in-
dustry” and “Local experts as an antidote to the industry’s
manipulative marketing strategies”.
The field notes provided additional data on the attitude of
local experts toward the industry while they were engaged
in continuous education activities; we present them separ-
ately.
All interviewees provided oral informed consent prior to
participating in the study. The Ethics Committee for Re-
search of the University Hospital Lausanne, Switzerland
considers that studies involving healthy subjects and not
addressing health issues do not require formal approval;
therefore, we requested none for this study.
Results
Unspecified quotes are from prescribing physicians; quotes
from local experts are indicated as LE1–4.
Criticism of the pharmaceutical industry
Physicians were highly critical of pharmaceutical compan-
ies, which they described as greedy, manipulative and dis-
honest. In their portrayal, the industry is ruthlessly focused
on profit, behaving “like sharks”. The “language of the in-
dustry” is all about “selling substances”: companies “want
to sell” and, therefore, “the information provided is not ob-
jective.” Rather, such information is unreliable and biased,
if not outwardly dishonest, and therefore “of no interest.”
For instance, the industry was accused of exaggerating
minor differences between competing drugs: “There are
few really differing drugs in the pharmacopoeia, contrary
to what the pharmas are claiming and want us to believe.”
The industry was criticised for publishing “dubious stud-
ies” which are “not of high scientific quality”. Physicians
also accused the industry of “hiding side effects to earn
millions with a drug.”
Prescribing physicians discussed the role of conferences
and experts in pharmacology as part of the marketing
strategies of pharmaceutical companies. These were con-
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sidered “over-represented at psychopharmacology confer-
ences.” Experts intervening at symposia were thought to be
“paid by the industry” or to just “want to get known.”
Local experts were equally critical. They said the phar-
maceutical companies conducted unscientific studies (“For
their new drugs pharmas conduct completely bogus stud-
ies,” LE4) for pure marketing purposes (“Some phase III
trials are a total marketing fabrication,” LE1).
Local experts also criticised opinion leaders, again de-
scribed as being used by the industry for marketing pur-
poses: “Opinion leaders are marketing products; really…If
they weren’t useful, pharmaceutical companies wouldn’t
spend so much money on them to promote their products”
(LE1). Opinion leaders were sometimes described as liars:
“It’s terrible to hear somebody telling you at a meeting that
antipsychotic X is better than all the others and the next day
the same person tells you that, no, in fact antipsychotic Y
is the best drug. This actually happens” (LE1). “Satellite
symposia” organised by the industry during scientific con-
ferences were described as one place where opinion leaders
were particularly active: “You never hear satellite sympo-
sia on topics that don’t interest the pharmaceutical industry;
it’s obvious they try to recruit good speakers who are fa-
miliar with the products they want to pitch” (LE2). Experts
on advisory boards were also cited as part of the industry’s
marketing strategy: “Advisory boards allow pharmas to ad-
apt their propaganda” (LE2).
In summary, both physicians and local experts were highly
critical of the pharmaceutical industry, which they de-
scribed as greedy, manipulative and dishonest. Opinion
leaders were mostly portrayed as marketing tools.
Local experts as an antidote to the industry’s
manipulative marketing strategies
Prescribing physicians spoke highly of local experts in psy-
chopharmacology whom they knew personally. They ex-
pressed appreciation for the continuing education offered
by the experts: “We have regular meetings with [LE2 and
LE4], which are very good”; “Psychopharmacological
Rounds [with LE2 and LE4], which are sponsored by a
pharmaceutical company, are an interesting option because
in fact they are clinical and pharmacology workshops
where we can interact with colleagues.” Local experts were
described as highly influential on their prescription prac-
tices: “The major part of my continuous training…comes
from weekly meetings…We deal with difficult situations
that might crop up and figure out a way to solve them with
a leader.” Most importantly, local experts were perceived
as critical and independent from the industry, an antidote
to its marketing strategy: “the view of [LE2] will prevail
over what a medical rep has told me or what I have read
on their advertising material.” Indeed, they were said to
help the participants develop a critical mind toward the in-
dustry: “I think I am becoming more skilled when I discuss
with colleagues in the quality circle…When told that such
molecule is miraculous, do this, do that, one must keep
a critical spirit…I learnt how to develop a critical spirit.”
(In the Swiss medical context, a “quality circle” is a group
of physicians who meet regularly to identify, analyse and
solve work-related problems.)
The local experts did not readily perceive themselves as
opinion leaders. They expressed some embarrassment
when the interviewer addressed the issue (“Do you define
yourself as an opinion leader?”): “It’s an awkward question
because it’s rather immodest…I can imagine having a
small regional impact” (LE1); “I don’t believe I have a sig-
nificant impact, I believe it’s up to others to say” (LE3); “I
don’t know” (LE4). The local experts asserted their intel-
lectual independence from the pharmaceutical industry and
its marketing strategies, mostly because of their personal
capacity to resist its influence: “Some of the things that the
pharmaceutical industry asks me to do, I will never do…I
won’t show my slides before my presentation” (LE1); “I’ve
never felt I had to give in to the industry” (LE3). Cospon-
soring was also mentioned as a counterweight to the in-
dustry: “All the lectures given here are multisponsored,
so we don’t depend on a specific company which might
threaten that if we say something bad about it we won’t
get money for lectures or inviting speakers, etc.” (LE4).
Guidelines were described as a way to remain neutral as
an educator: “In my presentations, I stick to the guidelines”
(LE2). Local experts claimed they could express them-
selves freely during their educational activities with pre-
scribers, and described themselves as critical: “In my latest
lecture, I think I made all the possible criticisms about the
industry” (LE1); “We don’t hesitate with [LE2] to say that
this is a bad molecule according to our experience, literat-
ure, etc.” (LE4).
Indeed, direct observation of continuing education events
confirmed that the local experts were critical of the industry
in general, as well as of specific drugs. In one session, LE1
denounced various practices of the industry (ghostwriting,
active withholding of information about side effects, fund-
ing of medical journal supplements). LE2 criticised two
specific drugs. LE4 named a company which had been
sentenced to a fine of US$4 billion for promoting non-
evidence-based indications for a named drug. LE3 ex-
pressed more neutral views but mentioned the monospon-
soring of his presentation as a limitation that the audience
should be aware of.
However, the local experts expressed awareness of ambi-
guity in their own relationship with the pharmaceutical in-
dustry. They described possible conflicts of interest, more
complex than purely financial ones, involving academic
prestige and research funding: “Some companies can help
you raise your profile, whether by promoting your re-
search, with grants or helping to get publications, etc.”
(LE1). “Research groups need to be financed for studies.
No funding: no study” (LE4). They also argued that the in-
terests of medicine and the general population align in part
with those of the industry. From that perspective, interests
are not necessarily in conflict: “of course, we serve the in-
dustry’s interests…epidemiologists, neuroscientists, genet-
icists…we do research not for the Good Lord, it has to be
useful…and that means business” (LE2).
Discussion
Prescribing physicians expressed a high degree of trust in
the local experts, who emerged as potent sources of know-
ledge and information. They were clearly perceived as an
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important, positive influence on prescription practices. In
that sense, the local experts in our sample can be con-
sidered the “educational” opinion leaders that we described
in the introduction. We believe, however, that the pharma-
ceutical industry considered them opinion leaders in the
more classical, “marketing” sense. The sales representat-
ives in the area regularly cite our experts as references. Fur-
thermore, and most importantly, the industry indeed spon-
sors the continuing education events that we observed. We
therefore think that our local experts offer an interesting
opportunity to explore how these competing definitions of
“opinion leadership” can be articulated.
The local experts criticised opinion leaders for being tools
of the pharmaceutical industry. Assuming a position of
modesty, they did not define themselves as opinion leaders
and, in contrast to the supposed complacency of the latter,
they claimed to keep their independence. Were they minim-
ising their own susceptibility to industry influence as well
as their role in marketing strategies? The literature reports
that opinion leaders struggle to perceive themselves as re-
taining independence and integrity despite their links with
the industry (using, for instance, rationalisation to over-
come cognitive dissonance [15]), and tend to underestimate
or minimise its influence on them [13, 15, 29]. Our local
experts emphasised the industry’s influence in general, but
asserted their own independence. And, indeed, they were
very critical of the pharmaceutical industry, both during in-
terviews and when they spoke to their colleagues at con-
tinuing education events. Because their critical attitude was
described repeatedly by prescribing physicians, we believe
it is unlikely to be due to an observer’s presence. Most im-
portantly, this critical attitude seems to contribute signific-
antlyto their credibility in the eyes of prescribing physi-
cians. Therefore, our results raise the following question:
what is the benefit to pharmaceutical companies of spon-
soring such vocal critics? In other words, were our local
experts, at the end of the day, beneficial or not to the in-
dustry’s interests? One of them addressed the issue:
“I think what they believe or hope is that, with all we are
doing, some interest is kept alive, drugs are prescribed, and
more or less correctly prescribed. If the prescriptions are
not correct they may be in trouble, so I feel this is the chief
reason they might have to be interested in us” (LE2).
In part, the suggestion here is that the industry wants phys-
icians to prescribe appropriately. It would, however, appear
somewhat naïve, considering all the criticism expressed
above about the conflicts of interest between the industry
and good clinical practice: if all the industry wants is better
prescriptions, there is no conflict of interest. But LE2’s sug-
gestion is more subtle: the industry might see a benefit in
the very existence of continuing education in psychophar-
macology, because it keeps alive an interest in prescription.
Indeed, the real efficacy of antidepressants in depression
has been seriously debated over past years [30]. Continu-
ing education events in psychopharmacology are occasions
to discuss drugs at length, and likely to strengthen the role
of medication in the physician’s armamentarium. From this
perspective, criticism from these local experts is not a prob-
lem for the industry, and to the extent that it legitimises
them in the eyes of prescribers, it is indeed beneficial. It
reinforces the message that prescribing is complex and im-
portant, that it must be done appropriately. In that sense, the
fact that experts criticise the industry is no guarantee their
message is not influenced, in the final analysis, by the very
marketing strategies that they are criticising.
This is, of course, speculation: we do not know why most
pharmaceutical companies active in the field choose to
sponsor our experts, nor evaluate the impact of our experts
on the volume of prescriptions for antidepressants in the
area. More general limitations of our study are the local
context, sampling strategy, and small sample size, which
can all limit generalisability. However, the interviewees’
criticism of the pharmaceutical industry comes as no sur-
prise [31]. And the importance of maintaining a critical
spirit toward it is probably a fairly common position among
physicians. Therefore, the relationship between being a vo-
cal critic of the industry and having legitimacy in the eyes
of peers is likely to hold true beyond our local context.
Our study suggests one possible pattern of the relationship
between physicians as prescribers, local experts and the
pharmaceutical industry. Prescribing physicians personally
know local experts, whom they trust because they are crit-
ical of the industry, and are therefore perceived as inde-
pendent and promoters of critical thinking. Local experts
are highly critical of the industry and do not perceive them-
selves as opinion leaders, whom they consider either cor-
rupt or manipulated. This strengthens their own feeling of
independence as well as their credibility. The industry sup-
ports local experts despite their criticism because it be-
lieves that the very existence of a continuing education in
psychopharmacology, and whatever is said there, increases
the volume of prescriptions, particularly for antidepress-
ants: thus, it is better to be criticised than to sink into obli-
vion. As Oscar Wilde said, “there is only one thing in the
world worse than being talked about, and that is not being
talked about” [32].
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Appendix
Direct observation of the experts engaged in continuing education activities: description of the events
“Psychopharmacology Rounds” (LE2 and LE4) are monthly meetings at a university psychiatric hospital, cosponsored by nine pharmaceutical
companies. Approximately 30 participants were present at the observed session. “Depression and Chronobiology” (LE1) was a symposium or-
ganized by a university hospital, held in a four-star hotel and cosponsored by two pharmaceutical companies. Approximately 50 participants
were present. “Largatidone: a modern antipsychotic” (LE3) was a symposium organised and sponsored by one pharmaceutical company produ-
cing a specific antipsychotic, also held in a four-star hotel. Approximately 30 participants were present. For all events, attendance was free and
food was offered. (The titles of the events have been slightly modified to ensure anonymity.)
Interview guide for the local experts
How do you define the concept of “opinion leader”?
--- What is an opinion leader?
What is the role of an opinion leader?
--- In regard to science, his medical colleagues, the wider society, and the pharmaceutical industry?
Is there a relationship between opinion leaders and the pharmaceutical industry?
--- How would you define it, from the perspective of the physician? Of the industry? Compulsory, forced, necessary, desirable, for the physician,
for the industry?
--- Are there conflicts of interest in this relationship? Of what nature? The relationship between the opinion leaders and the industry is main-
tained in spite of this, isn’t it? Is it because the relationship is in some way positive for the opinion leaders? If so, in what ways?
--- Does one serve the industry’s interests when one is an opinion leader?
--- How do you think such conflicts of interests can be eliminated or managed?
What is the situation of the opinion leader in his relationship with the industry?
--- Is this a “win-win” situation? One of financial binding and therefore constraints on the opinion leader’s message to his peers? One in which
objective or authentic transfer of knowledge can take place?
Do you think opinion leaders are part of the marketing strategies of the industry?
Do you define yourself as an opinion leader?
--- Are there examples of situations in which you act as an opinion leader that come to your mind? (Provide specific examples of continuing
education activities if the participant does not evoke them.)
--- We were previously talking about conflicts of interest. Do you identify such conflict in your own situation as an opinion leader?
--- You still maintain a relationship with the industry. What are the positive aspects of this relationship?
--- You mentioned previously that opinion leaders were part of the marketing strategies of the industry. Do you feel that you are serving the
industry’s interests? If not so, how do you do this?
--- How do you eliminate or manage the potential conflicts of interest that you are describing?
Is there anything you would like to add? A comment, an important dimension that we should have talked about during the interview?
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